Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes alopecia areata as a long-term, immune-mediated disorder characterized by non-scarring hair loss, often occurring in genetically predisposed individuals and possibly triggered by T-cell-mediated inflammation, environmental stressors, and genetic factors.

This study explains that alopecia areata, a long-term immune-mediated disorder causing patchy baldness, results from an immunological attack on hair follicles, often in genetically predisposed individuals, with a complex mix of immunological, environmental, and genetic factors involved in its development.

This source explores alopecia areata, an immune-mediated disorder causing patchy hair loss due to immunological attacks on hair follicles, with a complex interaction of genetic, environmental, and immunological factors, particularly T-cell-mediated inflammation, contributing to its onset.

In this research, the authors describe alopecia areata as a long-term, immune-mediated disorder that causes non-scarring hair loss due to an immunological attack on hair follicles, often occurring in genetically predisposed individuals and manifesting in childhood or early adulthood.

This abstract explains that alopecia areata is an immune-mediated condition causing non-scarring hair loss, typically in genetically predisposed individuals, with its etiology linked to immune dysregulation, environmental stressors, and genetic factors.

This source describes alopecia areata as a long-term, immune-mediated disorder causing non-scarring hair loss, often starting in childhood or early adulthood due to genetic predisposition and an immunological attack on hair follicles.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study found that in patients with alopecia areata, serum granulysin levels decreased significantly after treatment with tofacitinib and correlated with reduced disease severity, suggesting serum granulysin as an indicator of immunological activity and response to therapy.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

In this study, researchers explored the immunological mechanisms involved in alopecia areata and suggested that targeting immune responses, particularly using JAK inhibitors and other immunomodulatory drugs, could help achieve stable remission and improve patients' quality of life.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This case report describes a post-COVID syndrome patient who experienced symptoms like headache, joint pain, and swollen lymph nodes; treatment with Erbisol drugs reportedly alleviated symptoms and normalized immunological parameters.

This review provides an overview of genetics, causes, and treatment options for alopecia areata but reports no new clinical results and emphasizes the importance of support for those affected.

This article reviews treatments for alopecia areata, including corticosteroids and other immunomodulators, and reports no new experimental findings.

A man was diagnosed with a rare form of lupus after showing unique skin symptoms that responded well to treatment.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

This review discusses sex differences in immune response to respiratory viral infections, including SARS-CoV-2, and highlights that hormones like estrogen may provide females with better protection, but it reports no new results.

This review integrates studies on mouse models and human clinical observations to highlight the role of immune cells in skin development and how their dysregulation leads to skin disorders, suggesting potential therapeutic pathways for skin regeneration.

This study found that all examined biomarkers and clinical features were elevated in systemic lupus erythematosus patients, particularly ANA and Anti-dsDNA autoantibodies, but no single biomarker was sensitive or specific enough for diagnosis.

This study found that carbon nanotube impurities induced immunological toxicity in mice, whereas purified nanotubes showed good biocompatibility, suggesting high-temperature thermal treatment may improve nanotube biocompatibility.

This study concluded that the CXCL12–CXCR4 signaling pathway significantly contributes to hair loss in androgenetic alopecia and alopecia areata by promoting inflammation and fibrosis, whereas inhibiting this pathway can restore hair growth and follicle health.

This open-label study suggests that combining valproate, lamotrigine, and a benzodiazepine can significantly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This study observed that a targetoid polycyclic concentric hair regrowth pattern appeared in some male patients with alopecia areata following treatment, indicating a positive sign of recovery despite unclear etiopathogenesis.

This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.

This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.

This review discusses various skin changes during pregnancy, noting that while most are benign and resolve after childbirth, some may require careful medical management for the safety of the mother and fetus; it reports no new results.

This review discusses the challenges of skin graft acceptance and examines current strategies and alternatives for full-thickness skin replacement and repair, noting that immunological rejection remains a significant hurdle.

This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.